TMCnet News
CLBT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Cellebrite DI Ltd. (CLBT)Shareholders of Cellebrite DI Ltd. (CLBT) took losses when the stock sold off following Q2 2026 revenue of approximately $131.1 million and a reduction in the Company's full-year 2026 ARR and revenue guidance. If you held CLBT shares and lost money, you have rights and a limited window to assert them -- click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. In a Form 6-K filed February 11, 2026, the Company stated: "Our 2026 outlook reflects our conviction in accelerated ARR growth." The accompanying guidance projected FY2026 ARR growth of 18% to 19%. Reported 2025 ARR growth was 21%. When reporting its first quarter results on May 14, 2026, Cellebrite reaffirmed this guidance. CFO Bartner was quoted noted the company was "shifting gears to drive the second quarter with a myriad of exciting opportunities to accelerate our ARR, deliver strong operating results, and generate healthy free cash flow." Management later admitted the "acceleration did not materialize at the level we anticipated," and Cellebrite cut its full-year 2026 outlook accordingly. Levi & Korsinsky is investigating whether Cellebrite DI may not have adequately disclosed information concerning its ARR growth trajectory. Shareholders who purchased CLBT and suffered a loss are encouraged to have your losses reviewed at no cost, or contact Joseph E. Levi, Esq. at (212) 363-7500. Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com Frequently Asked Questions About the CLBT Investigation Q: Who is eligible to participate in the CLBT investigation? A: Investors who purchased CLBT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares. Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Cellebrite DI Ltd. made materially false or misleading statements regarding its 2026 ARR growth trajectory and full-year outlook. When the Company reported Q2 2026 revenue of approximately $131.1 million and lowered its full-year 2026 ARR and revenue guidance, the stock price declined. Q: Who is conducting the CLBT investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased CLBT securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors. Q: What do CLBT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation. Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices. Q: What if I already sold my CLBT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CLBT and sold at a loss may still participate in the investigation. Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either. Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence. Attorney Advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260817282833/en/ |
